ACC 2022 | APOLLO

Lipoprotein a (Lp a) is an important risk factor for atherothrombosis and atherosclerotic cardiovascular disease, but it has no approved treatments to this day.  

ACC 2022 | Estudio APOLLO

The aim of this randomized study in phase 1 was to assess adverse events and siRNA tolerance (small interfering RNA) to reduce liver production of Lp a and assess plasma concentration with different doses. 

It included 32 patients with Lp a serum values ≥ 150 nmol/l and no CAD. Mean age was 50 and 53% were women. Participants were randomized to receiving placebo and subcutaneous doses of 30 mg, 60 mg, 100 mg, 300 mg, and 600 mg of SLN360.

Primary end point was safety and tolerance. Secondary end point was changes in plasma concentration of Lp a at 150-day followup. 

There were no serious adverse events (the most frequent were headache, sore injection site and transient elevation of liver enzymes). As regards the secondary end point, Lp a saw a 70 and 80% reduction after the administration of 300 and 600 mg of SLN360 respectively. This was observed at followup up to 150 days. 

Read also: ACC 2022 – Estudio Complete Trial QoL: Revascularización completa en el SCACEST.

Finally, there was a 20-30% reduction of LDL and apoB as well.

Conclusion

In this phase 1 study with 32 participants with elevated Lp a and no CAD, siRNA SLN360 was well tolerated, and there was a reduction of plasma concentration of Lp a depending of the dose. We need further study to better assess safety and efficacy. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board, SOLACI.org .

Reference: Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...